Tatematsu Y - Search Results

1

Reduced expression of Dicer associated with poor prognosis in lung cancer patients.

Karube Y, Tanaka H, Osada H, Tomida S, Tatematsu Y, Yanagisawa K, Yatabe Y, Takamizawa J, Miyoshi S, Mitsudomi T, Takahashi T. Karube Y, et al. Among authors: tatematsu y. Cancer Sci. 2005 Feb;96(2):111-5. doi: 10.1111/j.1349-7006.2005.00015.x. Cancer Sci. 2005. PMID: 15723655 Free PMC article.

2

Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients.

Osada H, Tatematsu Y, Saito H, Yatabe Y, Mitsudomi T, Takahashi T. Osada H, et al. Among authors: tatematsu y. Int J Cancer. 2004 Oct 20;112(1):26-32. doi: 10.1002/ijc.20395. Int J Cancer. 2004. PMID: 15305372

3

A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation.

Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y, Takahashi T. Hayashita Y, et al. Among authors: tatematsu y. Cancer Res. 2005 Nov 1;65(21):9628-32. doi: 10.1158/0008-5472.CAN-05-2352. Cancer Res. 2005. PMID: 16266980

4

ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features.

Osada H, Tatematsu Y, Yatabe Y, Horio Y, Takahashi T. Osada H, et al. Among authors: tatematsu y. Cancer Res. 2005 Dec 1;65(23):10680-5. doi: 10.1158/0008-5472.CAN-05-1404. Cancer Res. 2005. PMID: 16322211

5

Roles of achaete-scute homologue 1 in DKK1 and E-cadherin repression and neuroendocrine differentiation in lung cancer.

Osada H, Tomida S, Yatabe Y, Tatematsu Y, Takeuchi T, Murakami H, Kondo Y, Sekido Y, Takahashi T. Osada H, et al. Among authors: tatematsu y. Cancer Res. 2008 Mar 15;68(6):1647-55. doi: 10.1158/0008-5472.CAN-07-5039. Cancer Res. 2008. PMID: 18339843

6

miR-375 is activated by ASH1 and inhibits YAP1 in a lineage-dependent manner in lung cancer.

Nishikawa E, Osada H, Okazaki Y, Arima C, Tomida S, Tatematsu Y, Taguchi A, Shimada Y, Yanagisawa K, Yatabe Y, Toyokuni S, Sekido Y, Takahashi T. Nishikawa E, et al. Among authors: tatematsu y. Cancer Res. 2011 Oct 1;71(19):6165-73. doi: 10.1158/0008-5472.CAN-11-1020. Epub 2011 Aug 19. Cancer Res. 2011. PMID: 21856745

7

Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers.

Mizuno K, Osada H, Konishi H, Tatematsu Y, Yatabe Y, Mitsudomi T, Fujii Y, Takahashi T. Mizuno K, et al. Among authors: tatematsu y. Oncogene. 2002 Apr 4;21(15):2328-33. doi: 10.1038/sj.onc.1205402. Oncogene. 2002. PMID: 11948416

8

Frequent and histological type-specific inactivation of 14-3-3sigma in human lung cancers.

Osada H, Tatematsu Y, Yatabe Y, Nakagawa T, Konishi H, Harano T, Tezel E, Takada M, Takahashi T. Osada H, et al. Among authors: tatematsu y. Oncogene. 2002 Apr 4;21(15):2418-24. doi: 10.1038/sj.onc.1205303. Oncogene. 2002. PMID: 11948426

9

Significant up-regulation of a novel gene, CLCP1, in a highly metastatic lung cancer subline as well as in lung cancers in vivo.

Koshikawa K, Osada H, Kozaki K, Konishi H, Masuda A, Tatematsu Y, Mitsudomi T, Nakao A, Takahashi T. Koshikawa K, et al. Among authors: tatematsu y. Oncogene. 2002 Apr 25;21(18):2822-8. doi: 10.1038/sj.onc.1205405. Oncogene. 2002. PMID: 11973641

10

Decreased expression of 14-3-3sigma in neuroendocrine tumors is independent of origin and malignant potential.

Yatabe Y, Osada H, Tatematsu Y, Mitsudomi T, Takahashi T. Yatabe Y, et al. Among authors: tatematsu y. Oncogene. 2002 Nov 28;21(54):8310-9. doi: 10.1038/sj.onc.1206014. Oncogene. 2002. PMID: 12447694

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

80 results

Search Page

Filters